Low-Intensity DOACs in VTE: Sapienza University Reports Long-Term Outcomes
Friends of Mediterranean Journal of Hematology and Infectious Diseases Group shared a post by on LinkedIn:
“Direct oral anticoagulants (DOACs) are widely used for the treatment and secondary prophylaxis of venous thromboembolism (VTE).
Nowadays, DOACs represent the gold standard for long-term anticoagulation, with low-intensity DOAC administration becoming increasingly used worldwide in such scenarios.
Although low-intensity apixaban and rivaroxaban are approved for clinical usage as secondary VTE prophylaxis, there is limited literature regarding their efficacy and safety with a long follow-up.
Here we report the long experience of Sapienza University in Rome.”
Read the full article here.
Article: Secondary Prophylaxis of Venous Thromboembolism (VTE) with low dose Apixaban or Rivaroxaban: Results from a patient population with more than 2 years of median follow-up
Authors: Alessandro Laganà, Giovanni Manfredi Assanto, Chiara Masucci, Mauro Passucci, Livia Donzelli, Alessandra Serrao, Erminia Baldacci, Cristina Santoro, Antonio Chistolini
Stay updated on the latest scientific advances in the field of thrombosis with Hemostasis Today.
-
Apr 6, 2026, 04:46Ursula Porage Dona: Bringing the Bleeding Disorders Community Together at WFH 2026 with NNHF
-
Apr 6, 2026, 04:17Arun V J: How War Reshaped Blood Transfusion
-
Apr 6, 2026, 03:57Isabella Cieri: How TEG Is Transforming Vascular Surgery Care
-
Apr 5, 2026, 19:00Kausik Ray: Comparing Lipid Management in France vs. Rest of Europe for High Cardiovascular Risk Patients
-
Apr 5, 2026, 18:22Omar Adwan: Systematic Approach to Blood Smear Examination
-
Apr 5, 2026, 18:05Heghine Khachatryan: Rethinking Hemostatic Targets in Pregnancy for von Willebrand Disease
-
Apr 5, 2026, 17:45Matthew Walls: Recognising CAD PRS as a New ‘Risk Enhancing Factor’ in the 2026 ACC/AHA Guidelines
-
Apr 5, 2026, 17:44Philip A. Chan: Occasional Heavy Drinking Leads to 3 Times Higher Liver Fibrosis Risk in MASLD
-
Apr 5, 2026, 17:42Josu de la Fuente: Real World Data Shows Significant Risk of Subsequent HCT in SCD and Thalassemia